Rachel Narozniak, MA

The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.

The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).

The Food and Drug Administration (FDA) has approved trilaciclib (Cosela; G1 Therapeutics, Inc.).